MOTS-c benefits: what the research has and has not shown

How to read a benefit claim

Three questions separate a finding from a claim: what was given, to whom, and what was measured. Applied to MOTS-c, the answers are usually synthetic peptide, to mice or cultured cells, and a laboratory marker. That is a legitimate result about a mouse. It becomes a misstatement when restated as a benefit for a person.

Metabolism, insulin and body weight

This is the most-studied area, with 104 indexed records. The discovery paper reported that MOTS-c-treated mice were protected against age-dependent and high-fat-diet-induced insulin resistance and against diet-induced obesity, with skeletal muscle as the apparent target [Lee et al. 2015].

In people, the relationship has been examined the other way around: studies compare circulating MOTS-c between groups. One genotype study found that men carrying the K14Q-producing variant had a higher prevalence of type 2 diabetes, concentrated among the least physically active [Zempo et al. 2021]. That is a correlation in a specific population, not a test of treatment.

The question is now being asked properly. A Phase 2a randomised, placebo-controlled trial in adults with prediabetes lists an oral-glucose-tolerance-derived insulin sensitivity index as a primary outcome, with estimated completion in 2028 [NCT07505745]. Until it reports, the honest answer on metabolic benefit in humans is that it is unknown. See the metabolic research in full.

Physical capacity and muscle

Mouse work reported improved physical performance across age groups, including when treatment started late in life [Reynolds et al. 2021]. A separate line of work linked MOTS-c to myostatin signalling through a CK2–PTEN–mTORC2–AKT–FOXO1 route in muscle cells, with lower plasma myostatin in treated obese mice and an inverse correlation between the two in human plasma [Kumagai et al. 2021].

The human component of that exercise work points in the opposite causal direction from the marketing claim: exercise was associated with higher natural MOTS-c, rather than MOTS-c producing exercise-like benefits in people [Reynolds et al. 2021]. See exercise research.

Other reported effects in animals and cells

• Thermogenesis. In cold-exposed mice, MOTS-c was associated with brown-fat thermogenic gene expression and white-fat browning, with the effect disturbed by ERK inhibition [Lu et al. 2019].
• Inflammatory signalling. Animal challenge models reported lower pro-inflammatory cytokines and higher IL-10, in settings as different as bacterial infection and endotoxin lung injury.
• Aging markers. Work in senescent cells and older animals is indexed under aging research.

These are findings about specific models under specific challenges. They do not aggregate into a general claim, and the number of papers reporting an effect is not evidence of its size or its relevance to humans.

What would change this page

A completed randomised controlled trial reporting a clinical outcome in people. When one publishes, it will be indexed as a tier A record and will appear at the top of the evidence explorer sorted by design. Nothing currently in the index meets that standard.